Home Page

The information was submitted to the public on September 16, 2019 at 18:45 CET

CellaVision AB (publ) announced on September 16, 2019, at 18:30 CET that the company has signed an agreement to acquire the French company RAL Diagnostics (RAL). The full-length press release is available at www.cellavision.com

In connection with the release analysts, investors and the media are hereby invited to a telephone conference and audio webcast at 11:00 CET where Zlatko Rihter, President & CEO, will present the planned acquisition.

The presentation will be in English via a conference call or audio webcast:
https://tv.streamfabriken.com/2019-09-17-cellavision-press-conference

Phone number for the conference:
SE: +46850558369
UK: +443333009263
US: +18335268397

No pre-registration is required. Please dial in 5-10 minutes prior to the scheduled start time to facilitate a timely start.

About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company´s 17 local market support organizations covering more than 30 countries. In 2018, sales were SEK 365 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list.
Read more at www.cellavision.com